Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.

Ratios

vs
industry
vs
history
PE Ratio 32.35
PBE's PE Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PBE: 32.35 )
Ranked among companies with meaningful PE Ratio only.
PBE' s PE Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 32.35
Current: 32.35
0
32.35
PE Ratio without NRI 32.35
PBE's PE Ratio without NRI is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PBE: 32.35 )
Ranked among companies with meaningful PE Ratio without NRI only.
PBE' s PE Ratio without NRI Range Over the Past 10 Years
Min: 0  Med: 0 Max: 32.35
Current: 32.35
0
32.35
PB Ratio 3.60
PBE's PB Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PBE: 3.60 )
Ranked among companies with meaningful PB Ratio only.
PBE' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 3.6
Current: 3.6
0
3.6

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.88
PBE's Dividend Yield % is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PBE: 0.88 )
Ranked among companies with meaningful Dividend Yield % only.
PBE' s Dividend Yield % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.9
Current: 0.88
0
0.9
5-Year Yield-on-Cost % 0.88
PBE's 5-Year Yield-on-Cost % is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PBE: 0.88 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
PBE' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0.9
Current: 0.88
0
0.9

More Statistics

Short Percentage of Float0.00%
52-Week Range $35.71 - 47.14
Shares Outstanding (Mil)5,250,000.00
» More Articles for PBE

Headlines

Articles On GuruFocus.com
GIKEN, Originator of Implant Method, Achieves Listing on First Section of Tokyo Stock Exchange Jul 20 2017 
SAP Raises Outlook - Q2 Total Revenue Up Double-Digit Jul 20 2017 
Celyad announces initiation of the SHRINK trial Jul 20 2017 
Inovio Announces Pricing of Public Offering of Common Stock Jul 19 2017 
Regulus Announces Pricing of Public Offering of Common Stock Jul 19 2017 
CenturyLink launches Managed Security Services 2.0 to help Asia Pacific organizations protect agains Jul 19 2017 
New Supermicro Rack Scale Design (RSD) Supports High-Density, High-Performance Pooled NVMe Storage Jul 19 2017 
Yext Appoints Eiji Uda to Lead Yext in Japan Jul 19 2017 
IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Mattel, Inc. Jul 19 2017 
5-DAY DEADLINE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Eco Science Solu Jul 19 2017 

More From Other Websites
What Drove Biogen Stock in 2Q17? Jul 10 2017
How Incyte’s Valuation Has Changed since 1Q17 Results Jun 14 2017
Changes in Ionis Pharmaceuticals’ Valuation after 1Q17 Jun 09 2017
ETF Flopper: Biotech Bungle May 05 2017
Time to Buy Biotech ETF? Mar 13 2017
Trump's Immigration Plans an Overhang on Biotech ETFs? Mar 02 2017
A Look at Incyte’s Product Portfolio Mar 01 2017
What Lies Ahead for Biotech ETFs in Trump Era? Jan 27 2017
Trump Attacks Biotech & Pharma: ETFs Bleed Jan 12 2017
What’s in Incyte’s Product Portfolio? Jan 09 2017
Neurocrine Biosciences Pursues Women’s Health Segment with Elagolix Dec 02 2016
Biotech ETFs Slumping on Q3 Results Nov 08 2016
4 Frightful ETFs of This Year Oct 27 2016
3 ETFs to Buy for a Media Merger Frenzy Oct 05 2016
M&A Activity, Passing Drug Trials Help Biotech ETFs Rebound Sep 12 2016
How Are Eli Lilly’s Business Segments Performing? Sep 01 2016
Why Did Hormel Foods Increase Its Fiscal 2016 Guidance? Aug 24 2016
The Zacks Analyst Blog Highlights: PureFunds ISE Junior Silver ETF, SPDR S&P Technology Hardware... Aug 23 2016
This Seasonal ETF Is Ripe For The Pickin' This Summer Jul 27 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK